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Introduction
Many women are keen to use herbal or ‘natural’ remedies,
either to prevent breast cancer or to assist in treating the
disease, but most remain unaware of the limited scientific
evidence surrounding the efficacy of these remedies, and
the potential drug interactions and adverse effects that
may result from their consumption. In many instances
these women rely on in-house sale staff of health food
shops to provide sufficient and accurate advice. However,
an article published in this issue of Breast Cancer
Research [1] provides data on the heterogeneity of advice
given by sales staff and the limited scientific evidence pro-
vided to purchasers of natural or herbal remedies. These
data are consistent with previous studies [2–4] and high-
light important issues regarding the misleading and poten-
tially harmful nature of the advice provided to breast
cancer patients by health food shops.
Risk versus benefit of ‘natural’ products
In the study published in this issue [1] a number of prod-
ucts were recommended, none of which are currently sup-
ported by scientific evidence to confer a health benefit.
Indeed, in many instances the potential for adverse effects
of the products were not discussed, or were drug interac-
tions addressed. The study raises significant concerns,
particularly following the recent publication of data from
the Women’s Health Initiative on the risk–benefit profile of
hormone replacement therapy (HRT) [5] and the confirma-
tion from the UK based Million Women Study that current
and recent use of HRT increases the risk for breast cancer
[6]. These data have been widely publicized in the press,
and the headlines produced from such studies may lead
women to seek dietary or herbal alternatives to drug thera-
pies such as HRT, under the assumption that ‘natural’
products are safe and effective.
Women are high consumers of alternative or complemen-
tary therapies [7], and thus breast cancer patients are par-
ticularly prone to purchasing such remedies. Many of
these remedies are based on folklore [8] and have not yet
been scrutinized to the scientific rigor that is required for
approval of drug therapies. In one study [9], conducted in
the USA, the prevalence of use of alternative therapies by
breast cancer patients was greatest in women with higher
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educational attainment and income. The key public health
issues arising from consumption of such remedies relate
to the potential for interactions of supplements with
current drug therapy [10], the potential adverse effects
associated with consumption, particularly at high doses
[11], the concurrent use of several alternative therapies,
the costs of such therapies, and the lack of disclosure of
such treatments by the patient to their doctor [12].
Alarmingly, only half of the breast cancer patients in one
USA-based study reported discussing their use of an
alternative therapy with their doctor [9]. Doctors must be
more aware that their breast cancer patients may be
seeking advice and treatment from sources outside con-
ventional medicine. Poor communication between patient
and doctor is therefore a potential area for improvement,
and doctors treating patients with breast cancer should
initiate a dialogue on alternative therapies to ensure that
optimal advice is given regarding treatment options.
Medical science continues to comb through nature’s array
of compounds for potential substances that may success-
fully prevent or treat breast cancer. To date, however,
most of the herbal remedies or alternative ‘natural’ prepa-
rations on sale to breast cancer patients have either not
been robustly tested in appropriately controlled clinical
studies or lack clinical data to support their use in breast
cancer [13,14]. Natural extracts are complex mixtures, and
stringent regulations on quality assurance, which apply to
drug therapies, are not currently enforced. Indeed, there is
evidence to suggest wide variability in the quality of avail-
able dietary supplements and herbal remedies, one
example of which is the poor correlation between actual
and reported content of commercially available dietary
phytoestrogen/isoflavone supplements [15].
Breast cancer patients are attracted to ‘natural’ or alterna-
tive therapies because of the perception that they are less
toxic than conventional prescribed medicines. Although
recent reports on the potential adverse effects and drug
interactions resulting from consumption of some natural
products [16–18] may have raised awareness within the
medical community of the need for appropriate clinical
trials to address the ratio of risk to benefit for these prepa-
rations, this information is unlikely to have filtered through
to staff and purchasers from health food shops. In particu-
lar, risk assessment for dose and duration of exposure
must be addressed to help define the ‘efficacious’ dose, if
indeed there is any. Health food shops are and will proba-
bly remain a frequent source for such products and health
advice, but to date they remain unregulated and their
employees require no formal education in medical or nutri-
tional science. Currently, the alternative therapy market is
governed by marketing, with no regulation to ensure the
efficacy or safety of the products on sale. In the future,
more formal training of such staff on adverse effects, drug
interactions and the limitations of the clinical data on the
products sold would help consumers to make a more
rational choice. From a manufacturing perspective, it
would be ideal to introduce more stringent regulations to
ensure that a health benefit can only be marketed follow-
ing the completion and publication of clinical studies to
define optimal dose and assure no potential adverse
effects or drug interactions. Doctors must be aware of
what products their patients are consuming, and instilling
the importance of openness between manufacturers of
alternative therapies and the medical community is impor-
tant for future cooperation.
With the increasing availability of medical and nutritional
information to consumers from the internet and other
sources, doctors must remain up-to-date on the available
complementary or alternative medicines their patients are
consuming and offer cautious advice on their use. There is
currently insufficient scientific evidence available to
suggest that alternative therapies are safe and effective for
either the prevention or treatment of breast cancer.
Because of this lack of efficacy and potential for adverse
effects, their use warrants caution, particularly in vulnera-
ble breast cancer patients.
Conclusion
Breast cancer patients, along with the public in general,
remain unaware that most of the herbal remedies and alter-
native natural preparations available have not been robustly
tested in carefully designed clinical studies. Natural
extracts are complex mixtures, and stringent regulations on
quality assurance, which apply to drug therapies, are not
currently enforced. For most of these products, we still do
not know whether they work, and studies are required to
define whether they are effective and safe and, if so, what
dose is required for such an effect. Until such evidence-
based data is available, their use merits caution, particularly
in vulnerable breast cancer patients.
Competing interests
None declared.
References
1. Mills E, Ernst E, Singh R, Ross C, Wilson K: Health food store
recommendations: implications for breast cancer patients.
Breast Cancer Res 2003, 5:R170-R174.
2. Gotay CC, Dumitriu D: Health Food store recommendations for
breast cancer patients. Arch Fam Med 2000, 9:692-699.
3. Stoffer S, Szpunar W, Coleman B, Mallos P: Advice from some
health food stores. JAMA 1980, 244:2044-2046.
4. US Food and Drug Administration: Unsubstantiated Claims and
Documented Health Hazards in the Dietary Supplements Market-
place. USA: Food and Drug Administration; 1993.
5. Writing Group of the Women’s Health Initiative Investigators:
Risks and benefits of estrogen plus progestin in healthy post-
menopausal women: principle results from the Women’s
Health Initiative randomized controlled trial. JAMA 2002, 288:
321-333.
6. Million Women Study Collaborators: Breast cancer and
hormone replacement therapy in the Million Women Study.
Lancet 2003, 362:419-427.302
Breast Cancer Research    Vol 5 No 6 Cassidy
7. Morris KT, Johnson N, Homer L, Walts D: A comparison of com-
plementary therapy use between breast cancer patients and
patients with other primary tumor sites. Am J Surg 2000, 179:
407-411.
8. Ernst E, Cassileth BR: The prevalence of complementary/alter-
native medicine in cancer: a systematic review. Cancer 1998,
83:777-782.
9. Lee MM, Lin SS, Wrensch MR, Adler SR, Eisenberg D: Alterna-
tive therapies used by women with breast cancer in four
ethnic populations. J Natl Cancer Inst 2000, 92:42-47.
10. Spaulding-Albright N: A review of some herbal and related
products commonly used in cancer patients. J Am Diet Assoc
1997, Suppl 2:S208-215.
11. Mathijssen RH, Verweij J, De Bruijn P, Loos WJ, Sparreboom A:
Effects of St. John’s Wort on irinotecan metabolism. J Natl
Cancer Inst 2002, 94:1247-1249.
12. Adler SR, Fosket JR: Disclosing complementary and alternative
medicine use in the medical encounter: a qualitative study in
women with breast cancer. J Fam Pract 1999, 48:453-458.
13. Kaegi E: Unconventional therapies for cancer: 1. Essiac. The
Task Force on Alternative Therapies of the Canadian Breast
Cancer Research Initiative. CMAJ 1998, 158:897-902.
14. Miller DR, Anderson GT, Stark JJ, Granick JL, Richardson D:
Phase I/II trial of the safety and efficacy of shark cartilage in
the treatment of advanced cancer. J Clin Oncol 1998,  16:
3649-3655.
15. Setchell KD, Brown NM, Desai P, Zimmer-Nechemias L, Wolfe
BE, Brashear WT, Kirschner AS, Cassidy A, Heubi JE: Bioavail-
ability of pure isoflavones in healthy humans and analysis of
commercial soy isoflavone supplements. J Nutr 2001,
Suppl:1362S-1375S.
16. US Food and Drug Administration: Risk of drug interactions
with St. John’s Wort. JAMA 2000, 283:1679.
17. Izzo AA, Ernst E: Interactions between herbal medicines and
prescribed drugs:a systematic review. Drugs 2001, 61:2163-
2175.
18. US Food and Drug Administration: Letter to Health Care Profes-
sionals. FDA Issues Consumer Advisory that Kava Products may
be Associated with Severe Liver Injury. USA: US Food and Drug
Administration, Office of Nutritional Products, Labelling and
Dietary Supplements; 2002.
Correspondence
Aedin Cassidy, Hugh Sinclair Human Nutrition Unit, School of Food
Biosciences, University of Reading, Whiteknights, Reading, RG6 6AP,
UK. Tel/fax: +44 (0)1234 870498; e-mail: cassidyaedin@hotmail.com